NovaBay Pharma Balance Sheet - Annual (NYSEMKT:NBY)

Add to My Stocks
$2 $0.6 (42.86%) NBY stock closing price Sep 21, 2018 (Closing)

The NovaBay Pharma balance sheet is a snapshot of the company's financial health at a given point of time, whereas the other two financial statements are for a particular accounting period. All three financial statements should be used to measure the financial performance of the company, and should form a part of the NovaBay Pharma stock analysis. Annual results are typically accompanied with the company releasing financial statements. The balance sheet shows total liabilities of $7.48M and shareholders equity of $2.59M. NovaBay Pharma revenue and NovaBay Pharma operating cash flow are important in understanding the financial capacity of the company.

View latest 10 year balance sheet data to check NovaBay Pharma financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Cash3.19M9.51M2.38M5.42M10.5M12.73M8.42M11.53M10.99M12.09M
Marketable Securities----2.55M4.13M5.71M1.27M--
Receivables3.62M2.12M------3.8M-
Inventory--1.34M-------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.66M1.96M--------
Total Current Assets
8.99M14.47M4.52M6.95M14.79M18.28M14.55M13.75M15.6M12.51M
Property Plant & Equipment--2.09M1.97M2.36M2.22M3.08M3.02M2.82M2.09M
Accumulated Depreciation--1.7M1.54M1.64M1.33M1.81M1.43M1.01M-
Net Property Plant & Equipment
------1.27M1.58M1.81M1.45M
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Intangibles----------
Deposits & Other Assets----------
Total Assets
10.07M15.38M5.07M7.53M15.65M19.23M15.96M15.51M17.52M13.96M
Notes Payable----------
Accounts Payable--2.48M1.86M1.67M-----
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses1.67M1.8M1.98M1.05M1.61M1.49M1.06M-1.22M1.16M
Income Taxes Payable----------
Other Current Liabilities2.84M2.06M---1.22M1.3M1.48M2.16M2.5M
Total Current Liabilities
4.97M4.32M4.63M3.34M3.62M3.17M2.83M2.72M4.03M4.48M
Mortgages----------
Deferred Taxes/Income-2.31M2.43M2.17M1.67M-1.06M2.3M-1.66M
Convertible Debt----------
Long-Term Debt--1.65M-------
Non-Current Capital Leases----------
Other Long-Term Liabilities1.7M1.64M1.45M-1.83M1.28M2.72M---
Total Liabilities
7.48M8.28M10.17M5.68M7.13M5.18M6.61M5.02M4.17M6.62M
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus113.51M110.61M85.38M72.87M64.43M54M42.38M38.46M37M33.71M
Retained Earnings-111.07M-103.67M-90.52M-71.54M-56.35M-40.31M-33.28M-28.19M-23.89M-26.58M
Treasury Stock----------
Other Liabilities-----0.01M-0.01M-0.04M-0.01M--
Shareholders Equity2.59M7.1M-5.09M1.84M8.51M14.04M9.34M10.49M13.34M7.34M
Total Liabilities & Shareholders Equity10.07M15.38M5.07M7.53M15.65M19.23M15.96M15.51M17.52M13.96M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Most investors just check the NovaBay Pharma stock price, and NovaBay Pharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the NovaBay Pharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like NovaBay Pharma owns and has monetary significance. NBY assets decreased from $15.38M in 2016 to $10.07M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case NovaBay Pharma's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for NBY stock stand at $7.48M.

NovaBay Pharma Balance Sheet - Key Ratios

Current ratio
3.52
Debt to equity ratio
0
Asset turnover ratio
0.87
Receivables turnover
5.9
Price to book ratio
7.15